All News

The expanded indication marks the first time an anti-PD-1 regimen has been approved in the first-line setting as both combination and monotherapy for squamous NSCLC, regardless of tumor PD-L1 expression status.

Officials with the FDA have approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

Hepatitis B virus infectivity can remain stable for up to 9 months and demonstrate high resilience to antiseptics.

Preliminary data show that treatment with anti-PD-1 inhibitors may be feasible in patients with HIV and cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Officials with the US FDA have approved canagliflozin (Invokana, Janssen) to reduce the risk of major adverse cardiovascular (CV) events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease.

The CDC offers 7 tips to avoid any health scares this season.

The action, FDA officials explained in a press release, is based on new data that suggest there is no longer a reasonable certainty that there is no harm from the use of lead acetate as a color additive.

This new indication also applies to the fixed-dose combinations of canagliflozin/metformin HCl (Invokamet) tablets and canagliflozin/metformin HCl extended-release (Invokamet XR) tablets.

Avelumab, an immune checkpoint inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, significantly improved progression-free survival in untreated renal cell carcinoma.

Under the proposed plan, Medicare payments for Part B drugs would be based on international prices.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Three hospitals made significant progress in reducing deaths associated with poor quality health care.

Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis.

Bijuva (estradiol and progesterone) is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

According to TherapeuticsMD, Bijuva is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Despite a decline in the rate of opioid prescribing, the CDC reports that the number of opioid related deaths continues to rise. The pharmacology and pharmacokinetics of prescription and illicit fentanyl could help to shed light on why the opioid epidemic has taken the path that it has.

Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.

Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.

New data show a survival benefit with pembrolizumab (Keytruda) as both a monotherapy and combination treatment with chemotherapy.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Officials with the FDA have approved Jazz Pharmaceuticals' Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 to 17 years with narcolepsy.

Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.

Costume contact lenses are gaining popularity, but there are concerns with these products.

Having a pharmacy that truly matters can make all the difference in the world to your patients, and to your bank account.

In the lexicon of management, the owner is the epitome of leadership. Yet surprisingly, according to the Harvard Business Review, little is known about this unique role.

Officials with the FDA have approved Jazz Pharmaceuticals' Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pediatric patients aged 7 to 17 years with narcolepsy.